<DOC>
	<DOC>NCT00323310</DOC>
	<brief_summary>The purpose of this study was to assess the safety and enhancing properties of the magnetic resonance imaging (MRI) contrast agent MultiHance in children aged 2 to 17 years having central nervous system (CNS) disorders.</brief_summary>
	<brief_title>Safety and Efficacy of MultiHance in Pediatric Patients</brief_title>
	<detailed_description />
	<mesh_term>Nervous System Diseases</mesh_term>
	<mesh_term>Central Nervous System Diseases</mesh_term>
	<criteria>Between 2 and 17 years of age Informed consent from parents Assent from patient where required Known or highly suspected disease of the CNS and referred for either cranial or spinal MRI examination Contraindication to MRI Undergoing MRI in an emergency situation Known allergy to one or more of the ingredients in MultiHance Sickle cell anemia moderate to severe renal impairment Received another investigational compound within 30 days Pregnancy Lactating females Likely to undergo an invasive procedure within 72 hours of receiving MultiHance</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>disease of the central nervous system (brain or spine)</keyword>
</DOC>